US Patent

US8642025 — Hepatitis C virus inhibitors

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2027-08-11 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for using compounds, including DACLATASVIR DIHYDROCHLORIDE, to treat hepatitis C virus (HCV) infection.

USPTO Abstract

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1724`	—	daclatasvir-dihydrochloride
`U-1724`	—	daclatasvir-dihydrochloride

Patent Metadata

Patent number: US8642025
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-11
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.